By Tia Lynn Ivey
Takeda, a Japan-based pharmaceutical company that recently took over the $1.2 billion biopharmaceutical plant that setup shop in the Stanton Springs Industrial Park, has earned a prestigious recognition on account of the new plasma-manufacturing plant.
“ Takeda’s Georgia Manufacturing Facility was recognized as a 2019 Honorable Mention Winner in the annual International Society of Pharmaceutical Engineers (ISPE) 2019 Facility of the Year Awards,” announced Gabe Khouli, communications lead for Takeda’s Georgia Manufacturing Facility.
Officials from Takeda’s Georgia plant are proud to be celebrated by the International Society of Pharmaceutical Engineers.
“Receiving this recognition from the ISPE is validation for the years of dedicated work that went into building and operationalizing the Georgia facility,” said Carlos Soto, Georgia Site Head. “ISPE specifically recognized the strong culture of safety that permeated this construction project, including a mindset of safety education. I want to thank our construction partners for the foundation they helped us create, and I’m proud to see the strong emphasis on safety continuing into operations day after day. I’m proud to be part of a company known for putting its patients and employees first.”
“After winning ISPE’s Facility of the Year Awards (FOYA) for two projects at the Los Angeles site in 2018, this year’s FOYA Honorable Mention Award for the Covington project in terms of the highest safety culture and achievement during the construction phase is further great recognition for Takeda’s engineering project execution,” said Gunter Baumgartner, Head of Global Engineering.”
The ISPE recognition comes on the heels of Takeda’s two recent FDA approvals to manufacture plasma-based medications. In June 2018, the plant, then owned by Shire, was approved to manufacture “GAMMAGARD Liquid,” a medication treating humoral immunodeficiency diseases by infusing patients with immunoglobulin G (IgG) antibodies, which protect the body from various infections.
Takeda received FDA approval for a second medication to be manufactured out of the Stanton Springs plant. The FDA approved the plant to make FLEXBUMIN, a medication to treat hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome (ARDS), and nephrosis), cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
“Takeda’s Georgia Manufacturing Facility, formerly owned by Shire, has received U.S. FDA approval to manufacture a second product, FLEXBUMIN.” said Khouli in March.
Takeda’s success is tied to Morgan County’s success. Morgan County is one of the four counties that comprises the Joint Development Authority (JDA) along with Walton, Newton and Jasper counties.
Morgan County is poised to receive over $141,000 dollars in 2020—a 15 percent share of the first tax revenues generated from Stanton Springs through Takeda.
The JDA anticipates a total of $945,000 from the first year of tax revenues generated through Takeda.